| pubmed-article:17488695 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17488695 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17488695 | lifeskim:mentions | umls-concept:C0079773 | lld:lifeskim |
| pubmed-article:17488695 | lifeskim:mentions | umls-concept:C1522690 | lld:lifeskim |
| pubmed-article:17488695 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17488695 | pubmed:dateCreated | 2007-5-9 | lld:pubmed |
| pubmed-article:17488695 | pubmed:abstractText | Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalcitrant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial enrolled 19 patients. We observed overall and complete response rates of 84.2% and 42.1% (with no significant differences between stage I-IIA and IIB-IV patients), and 11% grade III/IV toxicity. After a maximum 46 month-follow-up, median overall (OS), event-free (EFS) and progression-free (PFS) survival were 34, 18 and 19 months. OS, EFS and PFS rates at 46 months were 44%, 30% and 37% respectively. Peg-Doxo seems to be an active and safe principle that should be used in plurirelapsed, early stage-MF and in combination with other chemotherapeutic agents in advanced and aggressive CTCLs. | lld:pubmed |
| pubmed-article:17488695 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17488695 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17488695 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17488695 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17488695 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17488695 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17488695 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17488695 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17488695 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17488695 | pubmed:month | May | lld:pubmed |
| pubmed-article:17488695 | pubmed:issn | 1592-8721 | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:LeoniPietroP | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:PimpinelliNic... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:FilosaGiorgio... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:OffidaniMassi... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:GoteriGaiaG | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:AlteriniRenat... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:SimonacciMarc... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:BettacchiAlbe... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:RupoliSerenaS | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:PuliniStefano... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:RicottiGiusep... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:ScortechiniAn... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:TassettiAngel... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:Mozzicafreddo... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:GiacchettiAlf... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:BrandozziGiul... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:MulattieriSim... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:StronatiAndre... | lld:pubmed |
| pubmed-article:17488695 | pubmed:author | pubmed-author:NovelliNicoli... | lld:pubmed |
| pubmed-article:17488695 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17488695 | pubmed:volume | 92 | lld:pubmed |
| pubmed-article:17488695 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17488695 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17488695 | pubmed:pagination | 686-9 | lld:pubmed |
| pubmed-article:17488695 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:meshHeading | pubmed-meshheading:17488695... | lld:pubmed |
| pubmed-article:17488695 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17488695 | pubmed:articleTitle | Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. | lld:pubmed |
| pubmed-article:17488695 | pubmed:affiliation | Clinic of Hematology, Polytechnic University of the Marche, Medical School, Ospedali Riuniti Umberto I, G.M. Lancisi-G. Salesi, Ancona, Italy. stpulini@bigfoot.com | lld:pubmed |
| pubmed-article:17488695 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17488695 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17488695 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:17488695 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17488695 | lld:pubmed |
